It has been considered the most frequently correlated with tumorigenesis and is a promising molecular target for cancer therapies.7 While its activation is transient under physiological conditions, Stat3 becomes continuously activated in a high proportion of solid and haematopoietic malignancies (including breast, ovarian and prostate cancer), thus contributing to malignant transformation and progression. Here, STAT3 is linked to cancer.